Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
View Older Stories View More Recent Stories
-
GDEV Inc. (GDEV) Initiated Overweight at Cantor Fitzgerald
-
Cantor Fitzgerald Starts Fulcrum Therapeutics (FULC) at Overweight
-
Caledonia Mining Corporation Plc: Utilisation of the block admission in respect of ATM Sales Agreement
-
Form N-23C3A CANTOR FITZGERALD INFRAS For: May 17
-
Despegar.com (DESP) PT Raised to $17 at Cantor Fitzgerald
-
Cantor Fitzgerald Starts Abbvie (ABBV) at Overweight
-
Form 424B3 Cantor Fitzgerald Income
-
CAIS Hosts Third Annual Alternative Investment Summit for Independent Advisors
-
Form 13F-NT Cantor Fitzgerald Europe For: Mar 31
-
Form 13F-NT CANTOR FITZGERALD & CO. For: Mar 31
-
Form 13F-NT CANTOR FITZGERALD SECURI For: Mar 31
-
Form 13F-HR CANTOR FITZGERALD, L. For: Mar 31
-
Oncoinvent to Present at Cantor Fitzgerald Frontiers in Radiopharma Virtual Summit
-
Nyxoah SA (NYXH) PT Lowered to $17 at Cantor Fitzgerald
-
SoundThinking (SSTI) PT Lowered to $20 at Cantor Fitzgerald
-
Form 10-Q Cantor Fitzgerald Income For: Mar 31
-
Exagen (XGN) PT Raised to $7 at Cantor Fitzgerald
-
Sprott Physical Copper Trust Files Preliminary Prospectus for Proposed Initial Public Offering
-
Capricor Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
-
Aardvark Therapeutics Announces $85 Million Oversubscribed Series C Financing
-
Markforged Holding Corp. (MKFG) PT Lowered to $1.30 at Cantor Fitzgerald
-
Innoviz Technologies (INVZ) PT Lowered to $3 at Cantor Fitzgerald
-
Cantor Fitzgerald Upgrades EVgo, Inc. (EVGO) to Overweight
-
Cantor Fitzgerald Starts Perspective Therapeutics Inc (CATX) at Overweight
-
GP-Act III Acquisition Corp. Announces the Pricing of $250 Million Initial Public Offering
-
Orchid Island Capital Announces May 2024 Monthly Dividend and April 30, 2024 RMBS Portfolio Characteristics
-
Shoals Technologies Group (SHLS) PT Lowered to $14 at Cantor Fitzgerald
-
Rivian Automotive Inc (RIVN) PT Lowered to $15 at Cantor Fitzgerald
-
Cantor Fitzgerald Reiterates Overweight Rating on Datadog (DDOG)
-
Rubicon Technologies (RBT) Sells Fleet Technology Business Unit, Issues Preferred Equity
-
Rubicon Announces Sale of Fleet Technology Business Unit and Issuance of Preferred Equity
-
Capital Square Hires Industry Veteran John Dunn as Senior Regional Vice President, South Central Territory
-
Form 8-K Cantor Fitzgerald Income For: May 06
-
Belite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease (STGD1) and Geographic Atrophy (GA) and Perspectives On Tinlarebant
-
ADC Therapeutics SA (ADCT) Prices $105M Share and Warrant Offering at $4.9/sh
-
ADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded Warrants
-
Form 424B3 CANTOR FITZGERALD INFRAS
-
CIGNA (CI) PT Raised to $400 at Cantor Fitzgerald
-
Cerus (CERS) PT Raised to $4 at Cantor Fitzgerald
-
Sprout Social Inc. (SPT) PT Lowered to $46 at Cantor Fitzgerald
-
Cloudflare Inc. (NET) PT Lowered to $80 at Cantor Fitzgerald
-
Fortinet (FTNT) PT Lowered to $55 at Cantor Fitzgerald
-
Soleno Therapeutics (SLNO) Announces Pricing of $138 Mln Public Offering Of Common Stock
-
Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering Of Common Stock
-
Cantor is bullish on FSD, starts Tesla (TSLA) stock at buy
-
Cantor Fitzgerald Starts Tesla (TSLA) at Overweight, 'good entry-point for investors'
-
AMD (AMD) PT Lowered to $170 at Cantor Fitzgerald
-
Form EFFECT CANTOR FITZGERALD INFRAS
-
TriSalus Life Sciences (TLSI) Secures $50M Debt Financing with OrbiMed
-
TriSalus Life Sciences Secures up to $50 million of Debt Financing with OrbiMed to Support TriNavĀ® Infusion System Growth Initiatives

